Overview

An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection

Status:
Terminated
Trial end date:
2019-07-11
Target enrollment:
Participant gender:
Summary
EVHA T01 is an international, phase I/II, multicentre, multi-stage, double-blind study that will evaluate at least three experimental arms compared to placebo control in HIV-1 infected participants to see if one or more has a clinically relevant impact on the control of viral replication.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Collaborators:
Centre Hospitalier Universitaire Vaudois
European Commission
European Georges Pompidou Hospital
FIT Biotech Ltd.
Fred Hutchinson Cancer Research Center
Henri Mondor University Hospital
Imperial College London
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Istituto Nazionale Malattie Infettive Lazaro Spallanzani
Medical Research Council
Saint-Louis Hospital, Paris, France
Swiss Government
Universitätsklinikum Hamburg-Eppendorf
University College, London
Treatments:
Vaccines
Vedolizumab